<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName A++V2.4.dtd?>
  <?SourceDTD.Version 2.4?>
  <?ConverterInfo.XSLTName springer2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id>
      <journal-title-group>
        <journal-title>Cancer Immunology, Immunotherapy</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0340-7004</issn>
      <issn pub-type="epub">1432-0851</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3042096</article-id>
      <article-id pub-id-type="pmid">21267721</article-id>
      <article-id pub-id-type="publisher-id">968</article-id>
      <article-id pub-id-type="doi">10.1007/s00262-010-0968-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Symposium-In-Writing</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>2011: the immune hallmarks of cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Cavallo</surname>
            <given-names>Federica</given-names>
          </name>
          <address>
            <phone>+39-011-6706454</phone>
            <fax>+39-011-2365417</fax>
            <email>federica.cavallo@unito.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Giovanni</surname>
            <given-names>Carla</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nanni</surname>
            <given-names>Patrizia</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Forni</surname>
            <given-names>Guido</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lollini</surname>
            <given-names>Pier-Luigi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Clinical and Biological Sciences, University of Turin, Molecular Biotechnology Center, Via Nizza 52, 10126 Turin, Italy </aff>
        <aff id="Aff2"><label>2</label>Department of Experimental Pathology, Alma Mater Studiorum University of Bologna, Cancer Research Section, Viale Filopanti 22, 40126 Bologna, Italy </aff>
        <aff id="Aff3"><label>3</label>Department of Hematology and Oncologic Sciences &#x201C;L. &amp; A. Seragnoli&#x201D;, Alma Mater Studiorum University of Bologna, Cancer Research Section, Viale Filopanti 22, 40126 Bologna, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>26</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2011</year>
      </pub-date>
      <volume>60</volume>
      <issue>3</issue>
      <fpage>319</fpage>
      <lpage>326</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>11</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>12</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2011</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <p>Ten years after the publication of the position paper &#x201C;The hallmarks of cancer&#x201D; (Hanahan and Weinberg Cell 100:57&#x2013;70, <xref ref-type="bibr" rid="CR1">2000</xref>), it has become increasingly clear that mutated cells on their way to giving rise to a tumor have also to learn how to thrive in a chronically inflamed microenvironment, evade immune recognition, and suppress immune reactivity. Genetic and molecular definition of these three immune hallmarks of cancer offers the opportunity to learn how to deploy specific countermeasures to reverse the situation in favor of the immune system and, eventually, the patient. This new information could be channeled to address what seem to be the three major hallmarks for the immune control of cancer progression: effective procedures to activate immune reactivity; characterization of not-disposable oncoantigens; and counteraction of immune suppression.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Cancer</kwd>
        <kwd>Inflammation</kwd>
        <kwd>Immune surveillance</kwd>
        <kwd>Immune suppression</kwd>
        <kwd>Oncoantigens</kwd>
        <kwd>Tumor vaccine</kwd>
        <kwd>Antitumor antibodies</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>The immune hallmarks of cancer</title>
      <p>In an important position paper published in January 2000, Hanahan and Weinberg listed six alterations essential for malignant growth: self-sufficiency in growth signals, insensitivity to antigrowth signals, limitless replicative potential, ability to evade apoptosis, sustained angiogenesis, and ability to invade the tissues and metastasize [<xref ref-type="bibr" rid="CR1">1</xref>]. The ability to deal with immune mechanisms, however, was not included among these essential capabilities, but may be supposed to be acquired by most&#x2014;and perhaps all&#x2014;tumors. Because of the authoritative impact of this paper, these six hallmarks are usually quoted as the starting ground for new anticancer strategies, while the addition of other critical features of malignant tumors as hallmarks is often urged [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>In the 10&#xA0;years since the publication of the paper, it has become increasingly clear that both exploitation of immune mechanisms and evasion of immune surveillance are skills that cancer cells should acquire on their way to giving rise to a tumor. A comprehensive cellular, molecular, and genetic interpretation of the initially somewhat fuzzy evidence of the importance of such acquisition has also been worked out. Three such immune hallmarks are certainly required:<list list-type="order"><list-item><p>Ability to thrive in a chronically inflamed microenvironment</p></list-item><list-item><p>Ability to evade immune recognition</p></list-item><list-item><p>Ability to suppress immune reactivity</p></list-item></list></p>
      <p>These three capabilities and acquisition of the genetic changes required to put them into practice are constant and essential features of natural and experimental cancers. Their strength, however, may vary from one kind of tumor to another, and even more variable are the mechanisms through which the various types of cancer undertake these activities. Acquisition of a specific genome change, therefore, is not important, whereas acquisition of these capabilities is crucial, irrespective of the mechanisms involved.</p>
      <sec id="Sec2">
        <title>Ability to thrive in a chronically inflamed microenvironment</title>
        <p>Genetically modified mouse models show the intrinsic carcinogenic potency of inflammation [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref>] and permit molecular definition of several of the mechanisms whereby an incipient tumor takes advantage of an inflammatory microenvironment. Continual activation of leukocyte populations, triggered by unrelenting infections, tissue damage or the anomalous behavior of the mutated cells, contributes to the progression of neoplastic transformation with multiple mechanisms that range from reactive oxygen species to growth and angiogenic factors [<xref ref-type="bibr" rid="CR6">6</xref>]. The balance between immunity and inflammation is constantly altered during aging, with inflammation holding the center of the stage in old age when tumor incidence peaks [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <p>The importance of an inflammatory microenvironment is so strong that even the time frame within which an oncogene-addicted cell population gives rise to a tumor in transgenic mice is modulated by the reactive stroma that surrounds the cancer lesion [<xref ref-type="bibr" rid="CR9">9</xref>]. Inflammation and carcinogenesis are linked even in the absence of external inflammatory stimuli. Oncogene-driven signals activate intrinsic pro-inflammatory pathways that affect the time frame within which a carcinoma appears and progresses [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Genome-wide microarray analysis in transgenic mice identifies cytokine genes whose increased expression in the tumor microenvironment is naturally induced by the transformed cells and required for their progression [<xref ref-type="bibr" rid="CR11">11</xref>]. The inflammatory cytokines produced can be both involved in autocrine loops directly fueling tumor cell proliferation [<xref ref-type="bibr" rid="CR12">12</xref>] and released by immune/inflammatory cells recruited to the site of epithelial transformation [<xref ref-type="bibr" rid="CR13">13</xref>]. Inhibition of the NF-kB pathway in these immune cells modifies stroma cell components and limits tumor expansion [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p>
        <p>Murine molecular data are directly endorsed by many epidemiological studies in humans that link extrinsic and intrinsic inflammatory pathways with an increased risk of cancer [<xref ref-type="bibr" rid="CR16">16</xref>]. The increased risk of gastric cancer in the setting of bacterial infections is linked to the polymorphisms in genes coding for pro-inflammatory cytokines [<xref ref-type="bibr" rid="CR17">17</xref>]. These findings show how extrinsic and intrinsic inflammatory pathways conspire along the road to cancer. Molecular definition of the ways in which chronic inflammation contributes to viral, chemical, and intrinsic carcinogenesis in humans is opening up novel prospects for immunoprevention.</p>
      </sec>
      <sec id="Sec3">
        <title>Ability to evade immune recognition</title>
        <p>The immune surveillance theory was put forward in the 1960s. It defined the ability to identify and destroy nascent tumors as a central asset of the immune system [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], but later received an apparently deadly blow when no increase in tumor incidence was observed in athymic nude mice [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Work in the last 10&#xA0;years, however, has shown that these mice are not an appropriate model for the investigation of immune surveillance, while the employment of genetically modified mice to generate defined and stable immune defects has fully vindicated this theory. Mice with genetic alterations leading to complete T- and B-cell deficiencies are more prone to spontaneous and chemical carcinogenesis than wild-type mice [<xref ref-type="bibr" rid="CR22">22</xref>]. Additional gene defects affecting natural immune responses increase the risk of more aggressive and precocious tumors [<xref ref-type="bibr" rid="CR22">22</xref>]. Moreover, immune mechanisms hold occult cancer at bay for periods equivalent to the natural life span of the mouse, while temporary immunodepression allows it to progress [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
        <p>Immune surveillance mechanisms limit cancer development, but are not completely efficient. Tumors that eventually arise are those that are poorly or not-immunogenic [<xref ref-type="bibr" rid="CR24">24</xref>]. A critical feature that distinguishes occult neoplastic lesions from overt cancer is thus their susceptibility to immune control. The ability to evade is another hallmark of cancer.</p>
        <p>Data from patients with acquired immune deficiencies such as AIDS and post-transplant immune suppression show a dramatic increase in the incidence of several tumor types, including lung cancer, lymphoid tumors and tumors related to viral infections, such as Kaposi&#x2019;s sarcoma (human herpes virus-8) and anogenital carcinomas (human papilloma virus, HPV) [<xref ref-type="bibr" rid="CR25">25</xref>].</p>
        <p>In the last 10&#xA0;years, it has become evident that a tumor becomes aware of its susceptibility to immune attack and elaborates many defenses against it. These have now been defined in both cellular and molecular terms.</p>
        <p>The increasing instability of the genome of precancerous cells favors the emergence of clones of different immunogenicity. The poorly immunogenic ones are those that sneak through the meshes of immunosurveillance. The stealthiness of clinical tumors can be seen as one of the results of an effective immunosurveillance [<xref ref-type="bibr" rid="CR24">24</xref>]. The loss or rarefaction of the expression of the glycoproteins of the major histocompatibility complex (MHC) on the cell membrane is one of the mechanisms by which tumor stealthiness is acquired. In addition, it may result from the subversion of cell physiology as a consequence of the overexpression of oncogene-coded proteins [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], and alteration of antigenic peptide-processing machinery [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p>
        <p>Poor MHC glycoprotein expression and hampered antigenic peptide expression on the tumor cell surface frustrate direct recognition of tumor antigens by T cells and impede direct priming of an immune response by a tumor. Moreover, they make the effector phase of the T-cell reaction against tumor-associated antigens worthless. Blockage of these two functions is a crucial issue in tumor development since T-cell-mediated cytotoxicity is an effective mechanism of tumor inhibition.</p>
      </sec>
      <sec id="Sec4">
        <title>Ability to suppress immune reactivity</title>
        <p>As their growth hidden from immune recognition is not enough to allay their obsession with attacks on the part of the immune system, most&#x2014;all?&#x2014;tumors acquire the ability to release a series of factors and cytokines to subvert normal reaction mechanisms. When a tumor acquires the ability to release significant amounts of the colony-stimulating factors [<xref ref-type="bibr" rid="CR30">30</xref>] or the vascular endothelial growth factor [<xref ref-type="bibr" rid="CR31">31</xref>], it causes the expansion of a population of myeloid immature cells that may not only help tumors to suppress immune reaction but also aid in the construction of new blood vessels for tumor growth [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p>
        <p>Yet even this is not enough. Through direct release of transforming growth factor (TGF)-beta, IL-10, and indoleamine 2,3-dioxygenase (IDO), or through the activation of such secretions in myeloid-derived suppressor cells, tumor-associated macrophages and dendritic cells, a tumor converts na&#xEF;ve T cells into adaptive regulatory T (T<sub>Reg</sub>) cells. Expansion of these cells is another way by which a tumor holds back host reactivity [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
        <p>Tumors also exploit the physiologic role of natural T<sub>Reg</sub> cells to block immune reactions. These cells recognize with high affinity self-antigens and block the induction of autoimmunity. The overexpression of a few tolerated self-antigens, as happens during the expansion of tumor cells overexpressing oncogene products, leads to the activation of natural T<sub>Regs</sub>. Thus, both through the exploitation of a physiologic safeguard mechanism to control autoimmunity and the ability to convert na&#xEF;ve T cells into a suppressor population, a growing tumor biases the immune response toward immunosuppression. The activation of adaptive and natural T<sub>Reg</sub> cells is triggered by specific activation of their T-cell receptor. The T<sub>Reg</sub> suppressor mechanisms thus turned on are mediated by different functions:<list list-type="order"><list-item><p>Exposure on the cell membrane of molecules delivering negative signals (CTLA4 and LAG3) to dendritic cells. These signals inhibit the maturation of dendritic cells, block their expression of MHC and co-stimulatory molecules (CD80 and CD86) [<xref ref-type="bibr" rid="CR35">35</xref>], activate their ability to produce IDO that leads to the generation of the immunosuppressive mediator kynurenine, and indirectly suppress genes encoding IL-6 and TNF [<xref ref-type="bibr" rid="CR36">36</xref>].</p></list-item><list-item><p>Release of adenosine and the secretion of TGF-&#x3B2;, IL-10, and IL-35 that interfere with the activation and effector functions of T cells [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p></list-item><list-item><p>Secretion of granzymes and perforin that might have cytolytic effects on target T cells, as well as on dendritic cells [<xref ref-type="bibr" rid="CR35">35</xref>].</p></list-item></list></p>
        <p>The same group of signals triggers the activation and maintenance of anomalous functions of tolerogenic dendritic cells and tumor-associated macrophages. In this way, a growing tumor orchestrates a web of distinct but integrated suppressive activities.</p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>How to counteract the immune hallmarks of cancer</title>
      <p>The knowledge gained in the last 10&#xA0;years offers the opportunity to learn how to deploy specific countermeasures to reverse the situation in favor of the immune system and, eventually, the patient. This new information could be channeled to address what seem to be the three major hallmarks for the immune control of cancer progression:<list list-type="order"><list-item><p>Effective procedures to activate immune reactivity</p></list-item><list-item><p>Characterization of not-disposable oncoantigens</p></list-item><list-item><p>Counteract immune suppression.</p></list-item></list></p>
      <sec id="Sec6">
        <title>Effective procedures to activate immune reactivity</title>
        <p>Chronic inflammation can be dampened with anti-inflammatory drugs, which in some cases reduce the risk of cancer (sulindac, aspirin) [<xref ref-type="bibr" rid="CR38">38</xref>]. However, a more sensitive strategy is to re-orient inflammation from tumor promotion to a tumor-preventive reaction [<xref ref-type="bibr" rid="CR39">39</xref>&#x2013;<xref ref-type="bibr" rid="CR41">41</xref>]. Both passive (antibodies) and active (vaccines) immunization effectively protect the host from tumor onset [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. However, a much larger body of evidence favors active immunization.</p>
        <p>The high efficacy of vaccines in the prevention of infection by carcinogenic viruses and other infectious agents causing cancer is currently getting an extraordinary social impact. Vaccines aimed at removing an infective risk factor are being commonly used.</p>
        <p>Hepatocellular carcinoma accounts for more than 4% of all human cancers, and 80% of cases are associated with viral infection. Vaccination against hepatitis B virus (HBV) markedly reduced the incidence of post-hepatitis hepatocellular carcinoma [<xref ref-type="bibr" rid="CR44">44</xref>]. Since chronic inflammation plays a significant role in the onset of liver cancer that follows HBV infection, this vaccine can be viewed as a form of primary prevention of a carcinogenic chronic inflammation.</p>
        <p>HPV causes neoplastic disorders ranging from benign warts to malignant cervical and anogenital carcinomas [<xref ref-type="bibr" rid="CR45">45</xref>]. The worldwide implementation of vaccination programs against HPV began only a few years ago, and their long-term efficacy in the prevention of cervical carcinoma is not yet completely assessed. Initial results are extremely favorable, and almost complete prevention of carcinogenesis is foreseen [<xref ref-type="bibr" rid="CR46">46</xref>]. Current HPV vaccines are effective in cancer prevention but devoid of therapeutic efficacy. Vaccines able to cure cervical carcinomas are actively studied [<xref ref-type="bibr" rid="CR47">47</xref>].</p>
        <p>The Epstein&#x2013;Barr virus (EBV) is implicated in a variety of diseases worldwide: infectious mononucleosis in Western countries, nasopharyngeal carcinoma in Asia, Burkitt&#x2019;s lymphoma in Africa, and lymphoproliferative diseases in immunodeficient patients. The use of some promising candidate vaccines is being actively pursued [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>].</p>
        <p>While vaccines to prevent tumors related to an infectious agent are becoming a medical reality, a large series of studies on genetically engineered mice suggest that vaccines to prevent tumors not related to an infectious agent may also be a new form of prevention [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Numerous data on healthy mice carrying oncogenes that predestine to lethal cancer show that vaccines addressing oncogene products block the onset of neoplastic lesions. Repeated boosts of the vaccine afford a persistent protection that may last as long as the natural murine life span.</p>
        <p>Somewhat surprisingly, the T-cell-mediated cytotoxic response plays a minor role in the protection afforded by several of these vaccines. Since the target oncogene products are self molecules, they elicit a kind of split-tolerance that mainly causes the disappearance of high-affinity CD8<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR52">52</xref>]. In addition, this response is inhibited by the expansion of natural T<sub>Reg</sub> cells that recognize the target antigen as a self-protein [<xref ref-type="bibr" rid="CR53">53</xref>]. Therefore, most of the antitumor action elicited by preventive vaccines rests on the multiple direct and indirect antitumor activities of antibodies [<xref ref-type="bibr" rid="CR54">54</xref>&#x2013;<xref ref-type="bibr" rid="CR56">56</xref>].</p>
      </sec>
      <sec id="Sec7">
        <title>Characterization of not-disposable oncoantigens</title>
        <p>Vaccines that must elicit and sustain a virtually lifelong immune response carry the risk of downmodulation or loss of the target antigen by neoplastic cells. A suitable target antigen that preempts the loss of immune recognition should<list list-type="order"><list-item><p>have an essential role in tumor growth or progression;</p></list-item><list-item><p>be a target of cytotoxic cells and antibodies.</p></list-item></list></p>
        <p>We have chosen the term &#x201C;oncoantigens&#x201D; for tumor antigens that fulfill these two requirements [<xref ref-type="bibr" rid="CR50">50</xref>]. When carcinogenesis is driven by an oncoantigen, antigen-loss variants can occur, but their tumorigenic potential would be markedly impaired [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. In the later course of tumor progression, the driving role of the targeted oncogene can be taken by different genes [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], whose products, in turn, will offer further oncoantigen targets.</p>
        <p>Tumors evade T-cell recognition through the downmodulation of antigen-processing machinery and MHC glycoprotein expression. However, antibody recognition of accessible molecules is not affected, and antibodies still ensure a functional inhibition of the target oncoantigen together with the activation of complement-mediated cytotoxicity and ADCC. Class I oncoantigens expressed on the cell surface can be attacked by both antibodies and cell-mediated immunity and are probably the best target for a preventive vaccine [<xref ref-type="bibr" rid="CR50">50</xref>]. Class II oncoantigens are tumor-secreted molecules or molecules in the tumor microenvironment that play essential roles in tumor expansion [<xref ref-type="bibr" rid="CR61">61</xref>]. These can be targeted by antibodies but not by T-cell-mediated immunity. Class III oncoantigens are tumor molecules that cannot be reached by antibodies because of their intracellular localization, and thus can only be targeted by T cells [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p>
        <p>One could imagine that in the future, vaccines to prevent cancer will be administered to the general population, as is happening now to prevent infectious tumors. In a more realistic perspective, there are several human groups at risk of cancer that could benefit from specific vaccines, especially in the case of genetic risk, preneoplastic syndromes, cohorts of individuals previously exposed to environmental carcinogens, and cancer survivors with increased risk of a new primary tumor. Of particular interest appears the finding that a vaccine against ERBB2, an archetypal class I oncoantigen, impairs chemical carcinogenesis in hamsters since it may open a new way to treat healthy persons with a specific risk of a chemically induced cancer for whom no active therapeutic option exists at present [<xref ref-type="bibr" rid="CR64">64</xref>].</p>
      </sec>
      <sec id="Sec8">
        <title>Counteraction of immune suppression</title>
        <p>The efficacy of vaccines is diminished by the tumor-driven expansion of immunosuppressive cells, including T<sub>Reg</sub> and myeloid-derived suppressor cells (MDSC) [<xref ref-type="bibr" rid="CR50">50</xref>], that results in both a far less significant immune response and suppression of its effector arm [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Strategies that counteract suppression during vaccination can make the difference between a poorly effective vaccine and a sterilizing one. T<sub>Reg</sub> cells accumulate in both human and mouse tumors, as well as in secondary lymphoid organs, and are recruited [<xref ref-type="bibr" rid="CR67">67</xref>] and expanded by either the proliferation of preexisting T<sub>Reg</sub> cells [<xref ref-type="bibr" rid="CR68">68</xref>] or the conversion of CD25-negative T cells [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Tumor-driven T<sub>Reg</sub> cell expansion also changes the tumor-specific T-cell repertoire [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR70">70</xref>] and inhibits the reaction of low-avidity T cells against tumor antigens [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR69">69</xref>].</p>
        <p>When vaccination is coupled with T<sub>Reg</sub> depletion by the administration of anti-CD25 monoclonal antibody, a long-lasting tumor immunity is induced, and the antibody response is enhanced. In addition, the low-avidity CTL response against the immunodominant peptide is restored, due to the freeing of CD8<sup>+</sup> T cells from T<sub>Reg</sub> constraints [<xref ref-type="bibr" rid="CR53">53</xref>]. These effects of T<sub>Reg</sub> depletion render the vaccination efficacious at tumor stages at which vaccination alone is ineffective [<xref ref-type="bibr" rid="CR53">53</xref>]. Similarly, T<sub>Reg</sub> cell functional inhibition, by means of OX40 triggering, protects mice from subsequent tumor challenge and induces a complete rejection of already-established nodules [<xref ref-type="bibr" rid="CR71">71</xref>].</p>
        <p>T<sub>Reg</sub> are not the sole suppressive cells than can be attacked to counteract immune suppression. Myeloid-derived suppressor cells (MDSC) are an underdeveloped target of growing importance [<xref ref-type="bibr" rid="CR72">72</xref>&#x2013;<xref ref-type="bibr" rid="CR74">74</xref>]. It has been shown that powerful vaccines inhibit MDSC [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]; however, a more direct strategy can be more effective. Four lines of attack were outlined in a recent review [<xref ref-type="bibr" rid="CR76">76</xref>]: induction of MDSC maturation, inhibition of MDSC generation, accumulation, and suppressive function.</p>
        <p>The clinical use of antisuppressive approaches will benefit all cancer patients, in particular more advanced ones, who frequently display higher levels of immune suppression and suppressive cells. As novel immunotherapies are first tried in advanced patients, we think that the success rate of such clinical trials would be significantly enhanced by the simultaneous implementation of counter-suppression approaches.</p>
      </sec>
    </sec>
    <sec id="Sec9">
      <title>Conclusions and perspectives</title>
      <p>Can these three hallmarks lead to the formulation of immune procedures effective in tumor therapy? The emerging evidence shows that immune maneuvers can control cancer. This evidence is still scattered, but a series of recent reports suggest that immunotherapy is becoming a real option in the management of cancer patients. Vaccines of various kinds, in fact, have provided results equal or better than the most successful conventional treatments in a range of neoplastic diseases such as lymphomas [<xref ref-type="bibr" rid="CR77">77</xref>], melanomas [<xref ref-type="bibr" rid="CR78">78</xref>], prostate, and lung cancer [<xref ref-type="bibr" rid="CR79">79</xref>]. These results along with the approval by US FDA of an initial vaccine for cancer therapy [<xref ref-type="bibr" rid="CR80">80</xref>] will certainly spur fresh and even more rational strategies for vaccines in cancer therapy. It is thus predictable that new vaccines based on innovative technologies will progressively reach the efficacy of most conventional cancer therapies and spare patients from the devastating side effects of chemotherapy. In some cases, the cure afforded by a vaccine may prove to be even more effective, more persistent than chemotherapy.</p>
      <p>It is noteworthy that current preclinical and clinical results converge on the relevance of antibodies in antitumor immune responses [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. In the last 10&#xA0;years, Herceptin and other mAbs have become efficacious new drugs that are commonly used and provide incredibly high revenues [<xref ref-type="bibr" rid="CR83">83</xref>].</p>
      <p>The mechanism of antitumor activity of mAb is complex and depends on the targeted antigen. mAb against Class I and Class II oncoantigens not only functionally inhibit the activity of their targets and recruit antibody-dependent killer mechanisms and complement-dependent reactions but also recruit the host adaptive response and act to some extent as a vaccine [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Despite these important clinical results, most antitumor vaccines are still designed to trigger only cell-mediated immunity. It is remarkable that a clinical trial of the first approved vaccine revealed significant correlations between patient survival and specific antibody titers, but not T-cell responses [<xref ref-type="bibr" rid="CR80">80</xref>]. Probably, the time is ripe to integrate such &#x201C;humoral&#x201D; concepts in the design of new therapeutic cancer vaccines.</p>
      <p>In conclusion, appraisal of the immune hallmarks of cancer, and of the possible countermeasures, opens the doors not only to widespread cancer immunoprevention but also to innovative and more efficacious cancer immunotherapies.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p content-type="acknowledgment">This work was supported by the Associazione Italiana per la Ricerca sul Cancro (IG 5377 and IG 10353), the Italian Ministry for the Universities and Research, the Universities of Torino and Bologna, the Compagnia di San Paolo, the Dipartimento di Patologia Sperimentale dell&#x2019;Universit&#xE0; di Bologna (fondo &#x201C;Pallotti&#x201D;), the Regione Piemonte and the Italian Ministry of Health.</p>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hanahan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>The hallmarks of cancer</article-title>
          <source>Cell</source>
          <year>2000</year>
          <volume>100</volume>
          <fpage>57</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id>
          <pub-id pub-id-type="pmid">10647931</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lazebnik</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>What are the hallmarks of cancer?</article-title>
          <source>Nat Rev Cancer</source>
          <year>2010</year>
          <volume>10</volume>
          <fpage>232</fpage>
          <lpage>233</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc2827</pub-id>
          <pub-id pub-id-type="pmid">20355252</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maeda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kamata</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Leffert</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Karin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis</article-title>
          <source>Cell</source>
          <year>2005</year>
          <volume>121</volume>
          <fpage>977</fpage>
          <lpage>990</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2005.04.014</pub-id>
          <pub-id pub-id-type="pmid">15989949</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Greten</surname>
              <given-names>FR</given-names>
            </name>
          </person-group>
          <article-title>NF-kappaB: linking inflammation and immunity to cancer development and progression</article-title>
          <source>Nat Rev Immunol</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>749</fpage>
          <lpage>759</lpage>
          <pub-id pub-id-type="doi">10.1038/nri1703</pub-id>
          <pub-id pub-id-type="pmid">16175180</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grohmann</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Bronte</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Control of immune response by amino acid metabolism</article-title>
          <source>Immunol Rev</source>
          <year>2010</year>
          <volume>236</volume>
          <fpage>243</fpage>
          <lpage>264</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00915.x</pub-id>
          <pub-id pub-id-type="pmid">20636821</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Allavena</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sica</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Balkwill</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Cancer-related inflammation</article-title>
          <source>Nature</source>
          <year>2008</year>
          <volume>454</volume>
          <fpage>436</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="doi">10.1038/nature07205</pub-id>
          <pub-id pub-id-type="pmid">18650914</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caruso</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lio</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cavallone</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Franceschi</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Aging, longevity, inflammation, and cancer</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>2004</year>
          <volume>1028</volume>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1196/annals.1322.001</pub-id>
          <pub-id pub-id-type="pmid">15915584</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vasto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Carruba</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lio</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Colonna-Romano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Di</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Candore</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Caruso</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Inflammation, ageing and cancer</article-title>
          <source>Mech Ageing Dev</source>
          <year>2009</year>
          <volume>130</volume>
          <fpage>40</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1016/j.mad.2008.06.003</pub-id>
          <pub-id pub-id-type="pmid">18671998</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Owens</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Stamp</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Arnott</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>East</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Holdsworth</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rollins</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pasparakis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kollias</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Balkwill</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis</article-title>
          <source>Nat Med</source>
          <year>1999</year>
          <volume>5</volume>
          <fpage>828</fpage>
          <lpage>831</lpage>
          <pub-id pub-id-type="doi">10.1038/10552</pub-id>
          <pub-id pub-id-type="pmid">10395330</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cancer: Inflaming metastasis</article-title>
          <source>Nature</source>
          <year>2009</year>
          <volume>457</volume>
          <fpage>36</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="doi">10.1038/457036b</pub-id>
          <pub-id pub-id-type="pmid">19122629</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calogero</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Cordero</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice</article-title>
          <source>Breast Cancer Res</source>
          <year>2007</year>
          <volume>9</volume>
          <fpage>211</fpage>
          <pub-id pub-id-type="doi">10.1186/bcr1745</pub-id>
          <pub-id pub-id-type="pmid">17705881</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warren</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Shoemaker</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Shealy</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Bshar</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ip</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice</article-title>
          <source>Mol Cancer Ther</source>
          <year>2009</year>
          <volume>8</volume>
          <fpage>2655</fpage>
          <lpage>2663</lpage>
          <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0358</pub-id>
          <pub-id pub-id-type="pmid">19755514</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sangaletti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tripodo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ratti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Piconese</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Porcasi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Salcedo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Trinchieri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Chiodoni</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis</article-title>
          <source>Cancer Res</source>
          <year>2010</year>
          <volume>70</volume>
          <fpage>7764</fpage>
          <lpage>7775</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0471</pub-id>
          <pub-id pub-id-type="pmid">20924115</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pikarsky</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Porat</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Abramovitch</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Amit</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kasem</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gutkovich-Pyest</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Urieli-Shoval</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Galun</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ben-Neriah</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>NF-kappaB functions as a tumour promoter in inflammation-associated cancer</article-title>
          <source>Nature</source>
          <year>2004</year>
          <volume>431</volume>
          <fpage>461</fpage>
          <lpage>466</lpage>
          <pub-id pub-id-type="doi">10.1038/nature02924</pub-id>
          <pub-id pub-id-type="pmid">15329734</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greten</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Eckmann</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Greten</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>ZW</given-names>
            </name>
            <name>
              <surname>Egan</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Kagnoff</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Karin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer</article-title>
          <source>Cell</source>
          <year>2004</year>
          <volume>118</volume>
          <fpage>285</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2004.07.013</pub-id>
          <pub-id pub-id-type="pmid">15294155</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colotta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Allavena</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sica</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garlanda</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability</article-title>
          <source>Carcinogenesis</source>
          <year>2009</year>
          <volume>30</volume>
          <fpage>1073</fpage>
          <lpage>1081</lpage>
          <pub-id pub-id-type="doi">10.1093/carcin/bgp127</pub-id>
          <pub-id pub-id-type="pmid">19468060</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El-Omar</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Carrington</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>McColl</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Bream</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Herrera</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lissowska</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Rothman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lanyon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fraumeni</surname>
              <given-names>JF</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Rabkin</surname>
              <given-names>CS</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-1 polymorphisms associated with increased risk of gastric cancer</article-title>
          <source>Nature</source>
          <year>2000</year>
          <volume>404</volume>
          <fpage>398</fpage>
          <lpage>402</lpage>
          <pub-id pub-id-type="doi">10.1038/35006081</pub-id>
          <pub-id pub-id-type="pmid">10746728</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Lawrence</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title>Discussion</article-title>
          <source>Cellular and humoral aspects of the hypersensitivity states</source>
          <year>1959</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Hoeber-Herper</publisher-name>
          <fpage>529</fpage>
          <lpage>532</lpage>
        </mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burnet</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>The concept of immunological surveillance</article-title>
          <source>Prog Exp Tumor Res</source>
          <year>1970</year>
          <volume>13</volume>
          <fpage>1</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">4921480</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stutman</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice</article-title>
          <source>Science</source>
          <year>1974</year>
          <volume>183</volume>
          <fpage>534</fpage>
          <lpage>536</lpage>
          <pub-id pub-id-type="doi">10.1126/science.183.4124.534</pub-id>
          <pub-id pub-id-type="pmid">4588620</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rygaard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Povlsen</surname>
              <given-names>CO</given-names>
            </name>
          </person-group>
          <article-title>The nude mouse vs. the hypothesis of immunological surveillance</article-title>
          <source>Transplant Rev</source>
          <year>1976</year>
          <volume>28</volume>
          <fpage>43</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">1251462</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shankaran</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bruce</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Swanson</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Old</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>410</volume>
          <fpage>1107</fpage>
          <lpage>1111</lpage>
          <pub-id pub-id-type="doi">10.1038/35074122</pub-id>
          <pub-id pub-id-type="pmid">11323675</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koebel</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Vermi</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Swann</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Zerafa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rodig</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Old</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Smyth</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Adaptive immunity maintains occult cancer in an equilibrium state</article-title>
          <source>Nature</source>
          <year>2007</year>
          <volume>450</volume>
          <fpage>903</fpage>
          <lpage>907</lpage>
          <pub-id pub-id-type="doi">10.1038/nature06309</pub-id>
          <pub-id pub-id-type="pmid">18026089</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dunn</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Old</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>The three Es of cancer immunoediting</article-title>
          <source>Annu Rev Immunol</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>329</fpage>
          <lpage>360</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104803</pub-id>
          <pub-id pub-id-type="pmid">15032581</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grulich</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Leeuwen</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Falster</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Vajdic</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis</article-title>
          <source>Lancet</source>
          <year>2007</year>
          <volume>370</volume>
          <fpage>59</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61050-2</pub-id>
          <pub-id pub-id-type="pmid">17617273</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Norell</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Carlsten</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ohlum</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Malmberg</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Masucci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schedvins</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Altermann</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Handke</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Atkins</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Seliger</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kiessling</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity</article-title>
          <source>Cancer Res</source>
          <year>2006</year>
          <volume>66</volume>
          <fpage>6387</fpage>
          <lpage>6394</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0029</pub-id>
          <pub-id pub-id-type="pmid">16778217</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vertuani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Triulzi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Roos</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Charo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Norell</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lemonnier</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pisa</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Seliger</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kiessling</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice</article-title>
          <source>Cancer Immunol Immunother</source>
          <year>2009</year>
          <volume>58</volume>
          <fpage>653</fpage>
          <lpage>664</lpage>
          <pub-id pub-id-type="doi">10.1007/s00262-008-0587-1</pub-id>
          <pub-id pub-id-type="pmid">18820911</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garrido</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Algarra</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>MHC antigens and tumor escape from immune surveillance</article-title>
          <source>Adv Cancer Res</source>
          <year>2001</year>
          <volume>83</volume>
          <fpage>117</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="doi">10.1016/S0065-230X(01)83005-0</pub-id>
          <pub-id pub-id-type="pmid">11665717</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seliger</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanisms of MHC class I abnormalities and APM components in human tumors</article-title>
          <source>Cancer Immunol Immunother</source>
          <year>2008</year>
          <volume>57</volume>
          <fpage>1719</fpage>
          <lpage>1726</lpage>
          <pub-id pub-id-type="doi">10.1007/s00262-008-0515-4</pub-id>
          <pub-id pub-id-type="pmid">18408926</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicoletti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giovanni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lollini</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Bagnara</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Scotlandi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Landuzzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Del Re</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zauli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Prodi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nanni</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding</article-title>
          <source>Eur J Cancer Clin Oncol</source>
          <year>1989</year>
          <volume>25</volume>
          <fpage>1281</fpage>
          <lpage>1286</lpage>
          <pub-id pub-id-type="doi">10.1016/0277-5379(89)90074-6</pub-id>
          <pub-id pub-id-type="pmid">2806350</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melani</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chiodoni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <fpage>2138</fpage>
          <lpage>2145</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-01-0190</pub-id>
          <pub-id pub-id-type="pmid">12750171</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McLean</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Buckanovich</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Myeloid cells functioning in tumor vascularization as a novel therapeutic target</article-title>
          <source>Transl Res</source>
          <year>2008</year>
          <volume>151</volume>
          <fpage>59</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1016/j.trsl.2007.11.002</pub-id>
          <pub-id pub-id-type="pmid">18201673</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curiel</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mottram</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alvarez</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Moons</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Evdemon-Hogan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kryczek</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hoyle</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lackner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carmeliet</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>5535</fpage>
          <lpage>5538</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1272</pub-id>
          <pub-id pub-id-type="pmid">15313886</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colombo</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Piconese</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy</article-title>
          <source>Nat Rev Cancer</source>
          <year>2007</year>
          <volume>7</volume>
          <fpage>880</fpage>
          <lpage>887</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc2250</pub-id>
          <pub-id pub-id-type="pmid">17957190</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rochman</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Spolski</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>New insights into the regulation of T cells by gamma(c) family cytokines</article-title>
          <source>Nat Rev Immunol</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>480</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2580</pub-id>
          <pub-id pub-id-type="pmid">19543225</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wing</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sakaguchi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Regulatory T cells exert checks and balances on self tolerance and autoimmunity</article-title>
          <source>Nat Immunol</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>7</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1038/ni.1818</pub-id>
          <pub-id pub-id-type="pmid">20016504</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ernst</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Garrison</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
          <article-title>Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology</article-title>
          <source>J Immunol</source>
          <year>2010</year>
          <volume>185</volume>
          <fpage>1993</fpage>
          <lpage>1998</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.1000108</pub-id>
          <pub-id pub-id-type="pmid">20686167</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuzick</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Baron</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Burn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Greenwald</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jankowski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>La Vecchia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Meyskens</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Senn</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Thun</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement</article-title>
          <source>Lancet Oncol</source>
          <year>2009</year>
          <volume>10</volume>
          <fpage>501</fpage>
          <lpage>507</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70035-X</pub-id>
          <pub-id pub-id-type="pmid">19410194</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Palucka</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Marincola</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Tumour immunity: effector response to tumour and role of the microenvironment</article-title>
          <source>Lancet</source>
          <year>2008</year>
          <volume>371</volume>
          <fpage>771</fpage>
          <lpage>783</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(08)60241-X</pub-id>
          <pub-id pub-id-type="pmid">18275997</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muller-Hermelink</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Braumuller</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pichler</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wieder</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mailhammer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schaak</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ghoreschi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yazdi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haubner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sander</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Mocikat</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schwaiger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Forster</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Huss</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Kneilling</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rocken</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis</article-title>
          <source>Cancer Cell</source>
          <year>2008</year>
          <volume>13</volume>
          <fpage>507</fpage>
          <lpage>518</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccr.2008.04.001</pub-id>
          <pub-id pub-id-type="pmid">18538734</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beatty</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Narayanan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gariepy</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ranganathan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Finn</surname>
              <given-names>OJ</given-names>
            </name>
          </person-group>
          <article-title>Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer</article-title>
          <source>Cancer Prev Res (Phila)</source>
          <year>2010</year>
          <volume>3</volume>
          <fpage>438</fpage>
          <lpage>446</lpage>
          <pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-09-0194</pub-id>
          <pub-id pub-id-type="pmid">20332301</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katsumata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okudaira</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Samanta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Drebin</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Jolicoeur</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>MI</given-names>
            </name>
          </person-group>
          <article-title>Prevention of breast tumour development in vivo by downregulation of the p185neu receptor</article-title>
          <source>Nat Med</source>
          <year>1995</year>
          <volume>1</volume>
          <fpage>644</fpage>
          <lpage>648</lpage>
          <pub-id pub-id-type="doi">10.1038/nm0795-644</pub-id>
          <pub-id pub-id-type="pmid">7585144</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nanni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nicoletti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giovanni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Landuzzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Di</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pupa</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Ricci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Astolfi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Musiani</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lollini</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice</article-title>
          <source>J Exp Med</source>
          <year>2001</year>
          <volume>194</volume>
          <fpage>1195</fpage>
          <lpage>1205</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.194.9.1195</pub-id>
          <pub-id pub-id-type="pmid">11696586</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>You</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2009</year>
          <volume>101</volume>
          <fpage>1348</fpage>
          <lpage>1355</lpage>
          <pub-id pub-id-type="doi">10.1093/jnci/djp288</pub-id>
          <pub-id pub-id-type="pmid">19759364</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>zur Hausen</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Papillomaviruses and cancer: from basic studies to clinical application</article-title>
          <source>Nat Rev Cancer</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>342</fpage>
          <lpage>350</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc798</pub-id>
          <pub-id pub-id-type="pmid">12044010</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schiller</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Castellsague</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Villa</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Hildesheim</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results</article-title>
          <source>Vaccine</source>
          <year>2008</year>
          <volume>26</volume>
          <issue>Suppl 10</issue>
          <fpage>K53</fpage>
          <lpage>K61</lpage>
          <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.06.002</pub-id>
          <pub-id pub-id-type="pmid">18847557</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Welters</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kenter</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Steenwijk</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Lowik</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Berends-van der Meer</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Essahsah</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Stynenbosch</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Vloon</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Ramwadhdoebe</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Piersma</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Hulst</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Valentijn</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Fathers</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Drijfhout</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Franken</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Oostendorp</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fleuren</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Melief</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2010</year>
          <volume>107</volume>
          <fpage>11895</fpage>
          <lpage>11899</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1006500107</pub-id>
          <pub-id pub-id-type="pmid">20547850</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sokal</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Hoppenbrouwers</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vandermeulen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moutschen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Moreels</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haumont</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bollen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Smets</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Denis</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults</article-title>
          <source>J Infect Dis</source>
          <year>2007</year>
          <volume>196</volume>
          <fpage>1749</fpage>
          <lpage>1753</lpage>
          <pub-id pub-id-type="doi">10.1086/523813</pub-id>
          <pub-id pub-id-type="pmid">18190254</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rees</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tizard</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Cubitt</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Finerty</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Oyewole-Eletu</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Owen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Royed</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Shroff</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Tanday</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Middeldorp</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Amlot</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Steven</surname>
              <given-names>NM</given-names>
            </name>
          </person-group>
          <article-title>A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation</article-title>
          <source>Transplantation</source>
          <year>2009</year>
          <volume>88</volume>
          <fpage>1025</fpage>
          <lpage>1029</lpage>
          <pub-id pub-id-type="doi">10.1097/TP.0b013e3181b9d918</pub-id>
          <pub-id pub-id-type="pmid">19855249</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lollini</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Nanni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Vaccines for tumour prevention</article-title>
          <source>Nat Rev Cancer</source>
          <year>2006</year>
          <volume>6</volume>
          <fpage>204</fpage>
          <lpage>216</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc1815</pub-id>
          <pub-id pub-id-type="pmid">16498443</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Finn</surname>
              <given-names>OJ</given-names>
            </name>
          </person-group>
          <article-title>Cancer vaccines: between the idea and the reality</article-title>
          <source>Nat Rev Immunol</source>
          <year>2003</year>
          <volume>3</volume>
          <fpage>630</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="doi">10.1038/nri1150</pub-id>
          <pub-id pub-id-type="pmid">12974478</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rolla</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nicolo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Malinarich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Orsini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ria</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice</article-title>
          <source>J Immunol</source>
          <year>2006</year>
          <volume>177</volume>
          <fpage>7626</fpage>
          <lpage>7633</lpage>
          <pub-id pub-id-type="pmid">17114432</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rolla</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ria</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Occhipinti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Di</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Iezzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Spadaro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nicolo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ambrosino</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Merighi</surname>
              <given-names>IF</given-names>
            </name>
            <name>
              <surname>Musiani</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy</article-title>
          <source>J Immunol</source>
          <year>2010</year>
          <volume>184</volume>
          <fpage>6124</fpage>
          <lpage>6132</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.0901215</pub-id>
          <pub-id pub-id-type="pmid">20435927</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nanni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Landuzzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Nicoletti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giovanni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Croci</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Astolfi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Iezzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Di</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Musiani</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lollini</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent</article-title>
          <source>J Immunol</source>
          <year>2004</year>
          <volume>173</volume>
          <fpage>2288</fpage>
          <lpage>2296</lpage>
          <pub-id pub-id-type="pmid">15294941</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quaglino</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rolla</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Iezzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Spadaro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Musiani</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Giovanni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lollini</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Lanzardo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sanges</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Crispi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>De</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Calogero</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>113</volume>
          <fpage>709</fpage>
          <lpage>717</lpage>
          <pub-id pub-id-type="pmid">14991069</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Terabe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Munasinghe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Berzofsky</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas</article-title>
          <source>J Immunol</source>
          <year>2005</year>
          <volume>174</volume>
          <fpage>4228</fpage>
          <lpage>4236</lpage>
          <pub-id pub-id-type="pmid">15778385</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nanni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pupa</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Nicoletti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giovanni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Landuzzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Astolfi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ricci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>De</surname>
              <given-names>VR</given-names>
            </name>
            <name>
              <surname>Invernizzi</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Di</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Musiani</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Menard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lollini</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma</article-title>
          <source>Int J Cancer</source>
          <year>2000</year>
          <volume>87</volume>
          <fpage>186</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0215(20000715)87:2&lt;186::AID-IJC5&gt;3.0.CO;2-1</pub-id>
          <pub-id pub-id-type="pmid">10861472</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinstein</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Joe</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Oncogene addiction</article-title>
          <source>Cancer Res</source>
          <year>2008</year>
          <volume>68</volume>
          <fpage>3077</fpage>
          <lpage>3080</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-3293</pub-id>
          <pub-id pub-id-type="pmid">18451130</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kmieciak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Knutson</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Dumur</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Manjili</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses</article-title>
          <source>Eur J Immunol</source>
          <year>2007</year>
          <volume>37</volume>
          <fpage>675</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.200636639</pub-id>
          <pub-id pub-id-type="pmid">17304628</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Buzdar</surname>
              <given-names>AU</given-names>
            </name>
          </person-group>
          <article-title>Evolving novel anti-HER2 strategies</article-title>
          <source>Lancet Oncol</source>
          <year>2009</year>
          <volume>10</volume>
          <fpage>1179</fpage>
          <lpage>1187</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70315-8</pub-id>
          <pub-id pub-id-type="pmid">19959074</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cavallo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Calogero</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Are oncoantigens suitable targets for anti-tumour therapy?</article-title>
          <source>Nat Rev Cancer</source>
          <year>2007</year>
          <volume>7</volume>
          <fpage>707</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc2208</pub-id>
          <pub-id pub-id-type="pmid">17700704</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiarle</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Martinengo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mastini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ambrogio</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>D&#x2019;Escamard</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Inghirami</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination</article-title>
          <source>Nat Med</source>
          <year>2008</year>
          <volume>14</volume>
          <fpage>676</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="doi">10.1038/nm1769</pub-id>
          <pub-id pub-id-type="pmid">18469826</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <mixed-citation publication-type="other">Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, Nanni P (2011) Vaccines and other immunological approaches for cancer immunoprevention. Curr Drug Targets (in press)</mixed-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <mixed-citation publication-type="other">Berta GN, Sprio AE, Iezzi M, Spadaro M, Cappia S, Salamone P, Di Scipio F, Mognetti B, Papotti M, Musiani P, Forni G, Cavallo F (2011) A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. Cancer Prev Res (in press)</mixed-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shevach</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>CD4+ CD25+ suppressor T cells: more questions than answers</article-title>
          <source>Nat Rev Immunol</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>389</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="pmid">12093005</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zou</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Immunosuppressive networks in the tumour environment and their therapeutic relevance</article-title>
          <source>Nat Rev Cancer</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>263</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc1586</pub-id>
          <pub-id pub-id-type="pmid">15776005</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curiel</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Coukos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Alvarez</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mottram</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Evdemon-Hogan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Conejo-Garcia</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Burow</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kryczek</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Daniel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lackner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Disis</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Knutson</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</article-title>
          <source>Nat Med</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>942</fpage>
          <lpage>949</lpage>
          <pub-id pub-id-type="doi">10.1038/nm1093</pub-id>
          <pub-id pub-id-type="pmid">15322536</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghiringhelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Puig</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Roux</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Parcellier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Solary</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kroemer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chauffert</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zitvogel</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+ CD25+ regulatory T cell proliferation</article-title>
          <source>J Exp Med</source>
          <year>2005</year>
          <volume>202</volume>
          <fpage>919</fpage>
          <lpage>929</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20050463</pub-id>
          <pub-id pub-id-type="pmid">16186184</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zou</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Regulatory T cells, tumour immunity and immunotherapy</article-title>
          <source>Nat Rev Immunol</source>
          <year>2006</year>
          <volume>6</volume>
          <fpage>295</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.1038/nri1806</pub-id>
          <pub-id pub-id-type="pmid">16557261</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ercolini</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Ladle</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Manning</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Pfannenstiel</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Machiels</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bieler</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Emens</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Reilly</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Jaffee</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response</article-title>
          <source>J Exp Med</source>
          <year>2005</year>
          <volume>201</volume>
          <fpage>1591</fpage>
          <lpage>1602</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20042167</pub-id>
          <pub-id pub-id-type="pmid">15883172</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piconese</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Valzasina</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection</article-title>
          <source>J Exp Med</source>
          <year>2008</year>
          <volume>205</volume>
          <fpage>825</fpage>
          <lpage>839</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20071341</pub-id>
          <pub-id pub-id-type="pmid">18362171</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gabrilovich</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Nagaraj</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Myeloid-derived suppressor cells as regulators of the immune system</article-title>
          <source>Nat Rev Immunol</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>162</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2506</pub-id>
          <pub-id pub-id-type="pmid">19197294</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ostrand-Rosenberg</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity</article-title>
          <source>Cancer Immunol Immunother</source>
          <year>2010</year>
          <volume>59</volume>
          <fpage>1593</fpage>
          <lpage>1600</lpage>
          <pub-id pub-id-type="doi">10.1007/s00262-010-0855-8</pub-id>
          <pub-id pub-id-type="pmid">20414655</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeNardo</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Andreu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Coussens</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity</article-title>
          <source>Cancer Metastasis Rev</source>
          <year>2010</year>
          <volume>29</volume>
          <fpage>309</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="doi">10.1007/s10555-010-9223-6</pub-id>
          <pub-id pub-id-type="pmid">20405169</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cipriani</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fridman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bendtsen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dharmapuri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mennuni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pak</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mesiti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Forni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Monaci</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bagchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ciliberto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>La Monica</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Scarselli</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy</article-title>
          <source>Hum Gene Ther</source>
          <year>2008</year>
          <volume>19</volume>
          <fpage>670</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="doi">10.1089/hum.2007.127</pub-id>
          <pub-id pub-id-type="pmid">18533895</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ugel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Delpozzo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Desantis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Papalini</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Simonato</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sonda</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Zilio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bronte</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic targeting of myeloid-derived suppressor cells</article-title>
          <source>Curr Opin Pharmacol</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>470</fpage>
          <lpage>481</lpage>
          <pub-id pub-id-type="doi">10.1016/j.coph.2009.06.014</pub-id>
          <pub-id pub-id-type="pmid">19616475</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <mixed-citation publication-type="other">Schuster S, Neelapu S, Gause B, Muggia F, Gockerman J, Sotomayor E, Winter J, Flowers C, Stergiou A, Kwak L, for the BiovaxID Phase III study investigators (2009) Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol 27: 2</mixed-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartzentruber</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lawson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Conry</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gailani</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Riley</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vena</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hwu</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210&#xA0;M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>CRA9011</fpage>
        </mixed-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Couzin-Frankel</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Immune therapy steps up the attack</article-title>
          <source>Science</source>
          <year>2010</year>
          <volume>330</volume>
          <fpage>440</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="doi">10.1126/science.330.6003.440</pub-id>
          <pub-id pub-id-type="pmid">20966228</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kantoff</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Higano</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Shore</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Small</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Penson</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Redfern</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Dreicer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sims</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Frohlich</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Schellhammer</surname>
              <given-names>PF</given-names>
            </name>
          </person-group>
          <article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>363</volume>
          <fpage>411</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1001294</pub-id>
          <pub-id pub-id-type="pmid">20818862</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nelson</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Dhimolea</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Reichert</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Development trends for human monoclonal antibody therapeutics</article-title>
          <source>Nat Rev Drug Discov</source>
          <year>2010</year>
          <volume>9</volume>
          <fpage>767</fpage>
          <lpage>774</lpage>
          <pub-id pub-id-type="doi">10.1038/nrd3229</pub-id>
          <pub-id pub-id-type="pmid">20811384</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weiner</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Surana</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Monoclonal antibodies: versatile platforms for cancer immunotherapy</article-title>
          <source>Nat Rev Immunol</source>
          <year>2010</year>
          <volume>10</volume>
          <fpage>317</fpage>
          <lpage>327</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2744</pub-id>
          <pub-id pub-id-type="pmid">20414205</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <mixed-citation publication-type="other">Wikinvest (2010) <ext-link ext-link-type="uri" xlink:href="http://www.wikinvest.com/stock">www.wikinvest.com/stock</ext-link></mixed-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferris</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Jaffee</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Ferrone</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape</article-title>
          <source>J Clin Oncol</source>
          <year>2010</year>
          <volume>28</volume>
          <fpage>4390</fpage>
          <lpage>4399</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.27.6360</pub-id>
          <pub-id pub-id-type="pmid">20697078</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Mortenson</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Radkevich-Brown</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Sattar</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>YX</given-names>
            </name>
          </person-group>
          <article-title>The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity</article-title>
          <source>Cancer Cell</source>
          <year>2010</year>
          <volume>18</volume>
          <fpage>160</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccr.2010.06.014</pub-id>
          <pub-id pub-id-type="pmid">20708157</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
